A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell Lymphoma Clinical Trial

— PLACARD  

Official title:

Phase Ib/II Trial of Histone Deacetylase Inhibitor CXD101 in Combination With Programmed Cell Death Protein-1 Inhibitor Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03873025
• Other study ID #: UCL/17/0920
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: October 2019
• Est. completion date: April 2025

Study information

• Verified date: August 2021
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Trial Subjects (patients), will receive single infusions of pembrolizumab in combination with CXD101 every 3 weeks for two years or until disease progression or unacceptable toxicity develops.

Description:

Trial Subjects (patients) who are deemed eligible for the trial will initially be entered into the safety run-in stage of the trial. Up to 12 patients will be registered into the safety run-in stage, in cohorts of 3 patients at a time. 3 patients will be registered initially and will be administered a single infusion of pembrolizumab (200mg, day 1) in combination with CXD101 (20mg twice daily days 1 to 5). This is dose level 0. If 0 to 1 dose limiting toxicity (DLT) is observed, 3 more patients will be entered into the trial and treated at dose level 0. If 0 to 1 DLT is observed across all 6 patients, the maximum tolerated dose (MTD) will be declared and the expansion stage of the trial will be opened. If more than 1 DLT is observed at dose level 0, 3 patients will be recruited and treated at dose level -1. The CXD101 dose will be reduced by 25% (20mg in the morning and 10mg in the evening, days 1 to 5), while the pembrolizumab dose will remain the same (200mg, day 1). If 0 or 1 DLT is observed, 3 more patients will be recruited and treated at dose level -1. If 0 or 1 DLT is observed across all 6 patients the maximum tolerated dose will be declared and the expansion stage of the trial will be opened. If more than 1 DLT is observed at dose level -1 the combination will be deemed excessively toxic and no further patients enrolled. Once the MTD is declared, the cohort will be expanded and a further 33 patients will be treated at this dose level. Patients will continue to receive pembrolizumab and CXD101 at 3 weekly intervals for a maximum of 2 years or until disease progression or unacceptable toxicity develops. Patients on pembrolizumab will be seen every 3 weeks during trial treatment. Patients who progress will be seen annually for disease status. Patients completing treating or who stop treatment early for reasons other than disease progression will be followed every 3 months for up to one year after the end of treatment, and annually thereafter until end of trial is declared (when the last patient has completed 1 year follow up).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 2025
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Biopsy-confirmed DLBCL, relapsed/ refractory after =2 lines of prior therapy and not fit for ASCT or relapsed post ASCT. Eligible histologies include (a) diffuse large B-cell lymphoma NOS, (b) transformed indolent non-Hodgkin lymphoma (including Richter's transformation), (c) EBV positive DLBCL NOS, (d) high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations, (e) high grade B-cell lymphoma NOS & (f) primary mediastinal B-cell lymphoma

2. Measurable disease (of >15mm in a node or >10mm in extranodal tissue)

3. Age 18 years or over

4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

5. Adequate organ and bone marrow function: Hb >80g/L, neutrophils >1.0x10^9/L and platelets >75x10^9/L (without platelet transfusion support)

6. International normalised ratio (INR) or prothrombin time (PT) or Activated partial thromboplastin time (aPTT): =1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants

7. Adequate renal function: estimated creatinine clearance >60ml/min as calculated using the Cockroft-Gault equation

8. Adequate liver function, including:

1. Bilirubin =1.5 x upper limit of normal (ULN).

2. Aspartate or alanine transferase (AST or ALT) =2.5 x ULN

9. Negative serum or urine pregnancy test for women of childbearing potential (WOCBP)

10. Willing to comply with the contraceptive requirements of the trial

11. Written informed consent

Exclusion Criteria:

1. Post-transplant lymphoproliferative disorder

2. Women who are pregnant or breast feeding, or males expecting to conceive or father children at any point from the start of study treatment until 4 months after the last administration of study treatment

3. Patients with corrected QTc (QTcF or QTcB) interval >450msec

4. Clinically significant cardiac or respiratory disease:

1. Cardiac disease: Myocardial infarction, severe/unstable angina pectoris within 6 months prior to starting study treatment, NYHA class III-IV heart failure

2. Pulmonary disease causing = grade 2 dyspnoea or patient requiring oxygen

5. Known involvement of the central nervous system with lymphoma

6. Clinically significant active infection requiring antibiotic or antiretroviral therapy

7. Active autoimmune disease that has required systemic treatment in the past 2 years

8. History of (non-infectious) pneumonitis that required steroids or has current pneumonitis

9. History of immune hepatitis or myocarditis

10. Systemic anti-cancer therapy within 4 weeks prior to starting study treatment (12 weeks for CAR T-cells)

11. Prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids and not have had radiation pneumonitis.

12. Received a live vaccine within 30 days prior to starting study treatment

13. Have taken an IMP/investigational device within 4 weeks prior to starting study treatment

14. Major surgery within 4 weeks prior to starting study treatment

15. Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX 40, CD137)

16. Prior allogeneic haematopoietic stem cell transplant, solid organ allogeneic transplant or allogeneic CAR T-cell therapy. Prior use of autologous CAR T-cell therapy is allowed but patient must be = 12 weeks post infusion prior to starting study treatment

17. Diagnosis of prior immunodeficiency or organ-transplant requiring immunosuppressive therapy, or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness

18. Positive serology for hepatitis B or C unless (as) hepatitis B positive due to vaccination (HBsAb positive, all other tests negative) or (b) past hepatitis B infection with low risk of reactivation (HBsAb positive & HBcAb positive, other tests (including hepatitis B DNA) negative - PI/co-investigator approval needed

19. Severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients and/or a history of allergies to the excipients for CXD101

20. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator

21. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study

22. Non-haematological malignancy within the past 3 years with the exception of (a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer (b) carcinoma in situ of the cervix or breast, (c) prostate cancer of Gleason grade 6 or less with stable prostate-specific antigen levels; or (d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study such as localised transitional cell carcinoma of the bladder or benign tumours of the adrenal gland or pancreas

23. Current or prior use of immunosuppressive therapy within 7 days prior to start of treatment except the following: intranasal, inhaled, topical steroids or local steroid injections (eg. Intra-articular injection); systemic corticosteroids at physiologic doses (<10mg/day or less of prednisolone or equivalent)

24. Patient unable to swallow

Related Conditions & MeSH terms

• Diffuse Large B Cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse

Intervention

Combination Product:
• Pembrolizumab and CXD101
Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allow the immune system to destroy these cancer cells. CXD101 is a histone deacetylase (HDAC) inhibitor which kills cancer cells by blocking the vital functions of HDAC enzymes.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
University College, London	Celleron Therapeutics Ltd., Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety run in: Determine the maximum tolerated dose of CXD101 given in combination with pembrolizumab	MTD to be defined as the highest dose level where 0 or 1 Dose limiting toxicity is observed in 6 patients	During first cycle of CXD101 + pembrolizumab (each cycle lasts 21 days; assessment will take into account dose limiting toxicities reported at any time during the first 21 days of treatment)
Primary	Best Objective Response Rate	Proportion of patients achieving CR or PR during the first 6 cycles of CXD101 in combination with pembrolizumab using the RECIL criteria	From baseline to end of cycle 6 of treatment (approximately 18 weeks; each cycle lasts 21 days)
Secondary	Overall Response Rate at the end of 4 cycles	Overall Response of the combination of CXD101 and Pembrolizumab	From baseline to end of cycle 4 of treatment (approximately 12 weeks; each cycle lasts 21 days)
Secondary	Response Duration	Time from date of first response confirmation to the first date of progressive disease confirmation	From start of treatment to time of disease progression (any time during study participation, minimum 3 years)
Secondary	Best Overall Response at any time point	Best Overall Response of CXD101 in combination with Pembrolizumab	From baseline to end of treatment (up to 2 years)
Secondary	Best response at end of cycle 6 of treatment	CR, PR, MR, Stable Disease, Progressive Disease rates over 6 weeks of treatment	From baseline to end of cycle 6 of treatment (approximately 18 weeks; each cycle lasts 21 days)
Secondary	Progression Free Survival	Progression Free Survival at 1 year	52 weeks after commencement of CXD101 and Pembrolizumab
Secondary	Overall Survival	Overall survival at 1 year	52 weeks after commencement of CXD101 and Pembrolizumab
Secondary	Incidence of treatment-emergent adverse events (safety and tolerability)	Adverse events to be reported during and after treatment, coded using CTCAE v5.0	From start of CXD101 and Pembrolizumab until 5 months post-treatment